TABLE 2

Pharmacokinetic analyses: ANOVA comparison of geometric least-squares-mean ratios (90% confidence intervals)

Analyte ParameterConcomitant Administration1-Hour Separation2-Hour Separation3-Hour Separation
Acetylsalicylic acid
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
94.4% (86.0%, 103.5%)
85.1% (81.4%, 89.0%)
85.1% (81.4%, 89.0%)
NANA94.3% (85.9%, 103.4%)
98.3% (94.0%, 102.7%)
98.2% (94.0%, 102.7%)
Salicylic acid
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
103.7% (100.3%, 107.2%)
91.8% (90.0%, 93.5%)
91.7% (90.0%, 93.5%)
NANA101.4% (98.0%, 104.8%)
97.9% (96.0%, 99.8%)
97.5% (95.6%, 99.4%)
Furosemide
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
99.5% (89.8%, 110.3%)
91.1% (87.5%, 94.9%)
89.9% (86.5%, 93.5%)
NANA107.3% (96.8%, 118.9%)
101.3% (97.3%, 105.6%)
99.9% (96.1%, 103.9%)
R-Warfarin
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
105.5% (99.6%, 111.7%)
100.9% (98.2%, 103.7%
100.6% (95.9%, 105.6%
NANA100.7% (95.1%, 106.7%)
99.7% (97.0%, 102.5%)
99.7% (95.0%, 104.6%)
S-Warfarin
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
107.3% (96.5%, 119.3%)
98.0% (93.5%, 102.6%)
98.5% (93.2%, 104.2%)
NANA101.5% (91.3%, 113.0%)
98.9% (94.4%, 103.6%)
98.1% (92.8%, 103.8%)
Free dabigatran
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
87.8% (81.3%, 94.8%)
82.4% (77.3%, 87.8%)
82.6% (77.6%, 87.9%)
93.6% (84.0%, 104.0%)
88.5% (80.3%, 97.6%)
88.5% (80.4%, 97.5%)
111.0% (103.0%, 120.0%)
94.5% (88.7%, 101.0%)
94.6% (88.9%, 101.0%)
NA
Total dabigatran
Cmax (ng/mL)
AUC0-t (hour·ng/mL)
AUC0-inf (hour·ng/mL)
88.3% (81.5%, 95.7%)
82.4% (77.1%, 88.0%)
82.8% (77.7%, 88.2%)
95.6% (86.0%, 106.0%)
89.1% (80.9%, 98.1%)
89.2% (81.1%, 98.0%)
115.0% (107.0%, 125.0%)
97.9% (91.6%, 105.0%)
98.0% (91.9%, 104.0%)
NA
  • NA, not applicable.